University of Pennsylvania

Inovio Pharmaceuticals, Inc.

Vgx Pharmaceuticals, Inc.

Mathura P Ramanathan

David B Weiner

Niranjan Y Sardesai

Jian Yan

Bernadette Ferraro

Karuppiah Muthumani

Patricia A Brown

Douglas R Kern

Rodney A Bowling

Donghui Zhang

Joo-Sung Yang

Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same

Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.

DNA constructs eliciting immune response against flavivirus and effective adjuvants

Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.

Vaccines against multiple subtypes of dengue virus

Drug delivery compositions and methods of delivering compounds are disclosed. Vaccines and methods of immunizing individuals are disclosed. Compositions for drug delivery including gene therapy and methods of treating individuals using such compositions are disclosed.

Targeted particles and methods of using the same

Drug delivery compositions and methods of delivering compounds into a cell or into an individual are disclosed. Vaccines and methods of immunizing individuals are disclosed. Compositions for drug delivery including gene therapy and methods of treating individuals using such compositions are disclosed.

Substantially pure WIP-1 and its use in assays to identify PAP-1/WIP-1 interaction inhibitors or WIP-I/WNV Cp interaction inhibitors are disclosed. Compositions comprising antisense sequences to prevent expression of WIP-1 and methods of treating cancer using the same are disclosed.

Growing community of inventors

Ardmore, PA, United States of America

Mathura P Ramanathan